AKEBIA THERAPEUTICS, INC. Operating Lease Cost
AKEBIA THERAPEUTICS, INC. (AKBA) reported Operating Lease Cost of $1.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $1.40M, a 16.67% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $1.20M, a 0.00% change year-over-year.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $3.80M, a 192.31% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $1.20M, a 67.57% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $5.00M, a 0.00% change from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $5.00M, a 12.28% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $5.70M, a 19.72% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $7.10M, a 5.97% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-05 | $2.70M 10-Q · filed 2026-08-05 | $6.40M derived: sum of 3 quarters · filed 2026-08-05 | $7.60M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-07 | $5.00M derived: sum of 2 quarters · filed 2026-05-07 | $6.20M derived: sum of 3 quarters · filed 2026-05-07 | $7.40M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.00M derived: sum of 2 quarters · filed 2026-02-26 | $6.20M derived: sum of 3 quarters · filed 2026-08-05 | $5.00M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-10 | $2.40M derived: sum of 2 quarters · filed 2026-08-05 | $1.20M 10-Q · filed 2025-11-10 | $4.90M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $1.20M 10-Q · filed 2026-08-05 | $2.50M 10-Q · filed 2026-08-05 | $1.20M 10-Q · filed 2025-08-07 | $3.70M derived: sum of 3 quarters · filed 2026-08-05 | $7.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-08 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $6.20M derived: sum of 3 quarters · filed 2026-02-26 | $8.70M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.00M derived: sum of 2 quarters · filed 2026-02-26 | $7.50M derived: sum of 3 quarters · filed 2026-02-26 | $5.00M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $3.70M 10-Q · filed 2025-11-10 | $1.20M 10-Q · filed 2024-11-07 | $6.20M derived: sum of 2 quarters · filed 2025-11-10 | $3.70M 10-Q · filed 2025-11-10 | $8.70M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $2.50M 10-Q · filed 2025-08-07 | $1.20M 10-Q · filed 2024-08-08 | $2.50M 10-Q · filed 2025-08-07 | $5.00M derived: sum of 3 quarters · filed 2026-02-26 | $6.20M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $1.20M 10-Q · filed 2024-05-09 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $3.70M derived: sum of 3 quarters · filed 2026-02-26 | $5.10M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $3.90M derived: sum of 3 quarters · filed 2026-02-26 | $5.70M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $1.20M 10-Q · filed 2024-11-07 | $2.60M derived: sum of 2 quarters · filed 2024-11-07 | $4.40M 10-Q · filed 2024-11-07 | $6.10M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $1.40M 10-Q · filed 2024-08-08 | $3.20M 10-Q · filed 2024-08-08 | $4.90M derived: sum of 3 quarters · filed 2024-08-08 | $6.70M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $1.80M 10-Q · filed 2024-05-09 | $3.50M derived: sum of 2 quarters · filed 2024-05-09 | $5.30M derived: sum of 3 quarters · filed 2024-05-09 | $7.10M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.50M derived: sum of 2 quarters · filed 2024-03-14 | $5.30M derived: sum of 3 quarters · filed 2024-03-14 | $7.10M 10-K · filed 2024-03-14 | ||
| 2022-09-30 | $1.80M 10-Q · filed 2023-11-08 | $3.60M derived: sum of 2 quarters · filed 2023-11-08 | $5.40M 10-Q · filed 2023-11-08 | $7.10M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $1.80M 10-Q · filed 2023-08-28 | $3.60M 10-Q · filed 2023-08-28 | $5.30M derived: sum of 3 quarters · filed 2023-08-28 | $7.00M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2022-03-31 | $1.80M 10-Q · filed 2022-05-09 | $3.50M derived: sum of 2 quarters · filed 2023-08-28 | $5.20M derived: sum of 3 quarters · filed 2023-08-28 | $6.90M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2021-12-31 | $1.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $3.40M derived: sum of 2 quarters · filed 2023-08-28 | $5.10M derived: sum of 3 quarters · filed 2023-08-28 | $6.70M 10-K/A · filed 2023-08-28 | ||
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-03 | $3.40M derived: sum of 2 quarters · filed 2022-11-03 | $5.00M 10-Q · filed 2022-11-03 | $6.80M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2021-06-30 | $1.70M 10-Q · filed 2022-08-04 | $3.30M 10-Q · filed 2022-08-04 | $5.10M derived: sum of 3 quarters · filed 2023-08-28 | $6.80M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2021-03-31 | $1.70M 10-Q · filed 2022-05-09 | $3.40M derived: sum of 2 quarters · filed 2023-08-28 | $5.10M derived: sum of 3 quarters · filed 2023-08-28 | $6.80M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2020-12-31 | $1.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $3.40M derived: sum of 2 quarters · filed 2023-08-28 | $5.10M derived: sum of 3 quarters · filed 2023-08-28 | $6.70M 10-K/A · filed 2023-08-28 | ||
| 2020-09-30 | $1.70M 10-Q · filed 2021-11-04 | $3.40M derived: sum of 2 quarters · filed 2021-11-04 | $5.00M 10-Q · filed 2021-11-04 | $6.70M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $1.70M 10-Q · filed 2021-08-05 | $1.60M 10-Q · filed 2020-08-10 | $3.30M 10-Q · filed 2021-08-05 | $5.00M derived: sum of 3 quarters · filed 2021-08-05 | $6.70M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.70M 10-Q · filed 2021-05-10 | $3.30M derived: sum of 2 quarters · filed 2021-05-10 | $5.00M derived: sum of 3 quarters · filed 2021-05-10 | $6.60M derived: sum of 4 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.30M derived: sum of 2 quarters · filed 2021-02-25 | $4.90M derived: sum of 3 quarters · filed 2021-02-25 | $6.60M 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $1.70M 10-Q · filed 2020-11-05 | $3.30M derived: sum of 2 quarters · filed 2020-11-05 | $5.00M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-10 | $3.30M 10-Q · filed 2020-08-10 | $3.30K 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $1.70M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |